Valued at USD 23.70 billion in 2024, the opioid market is projected to reach USD 24.14 billion in 2025 and USD 28.45 billion by 2034, growing at a CAGR of 1.8% during the forecast period 2025–2034, according to Polaris Market Research. Formulation advances and a broadening product portfolio are shaping competition. Key players include Aurobindo Pharma Limited, Assertio Therapeutics, Inc., AbbVie Inc., Amneal Pharmaceuticals LLC, Boehringer Ingelheim International GmbH, Fresenius Kabi, Mallinckrodt Pharmaceuticals, Endo International plc, Johnson & Johnson Corporation, Pfizer Inc., Purdue Pharma L.P., Sun Pharmaceutical Industries Limited, Trevena Inc., and Teva Pharmaceutical Industries Ltd.

Formulation Innovation and Delivery Methods

The report states that advances in formulations are improving accessibility for a broader population. Innovations in drug delivery, including extended-release products and transdermal patches, are making opioid medications more effective and easier to use. These advances improve patient compliance and support treatment in settings such as hospitals and home care. Rising awareness of treatment options and accessibility in rural and underserved areas are described as further drivers of market growth.

The report also points to an increasing focus on developing non-addictive opioid alternatives. This addresses safety concerns and is encouraging more healthcare providers to adopt these medications, which Polaris expects to influence opioid prescriptions during the forecast period.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/opioid-market

Product and Class Diversity

The market is segmented by class into natural, semi-synthetic, and fully synthetic opioids. By product, the report covers codeine, fentanyl, oxycodone, methadone, morphine, hydrocodone, tramadol, propoxyphene, and others. By release type, it distinguishes immediate-release opioids, also described as short-acting, from long-acting products, giving suppliers a framework for benchmarking portfolios across therapeutic needs.

Application Breadth

The application segmentation extends beyond general relief. It includes cancer pain, with sub-segments covering brain, breast, colorectal, blood, skin, and prostate cancers, as well as neuropathic, migraine, orthopedic and musculoskeletal, arthritis, and fibromyalgia indications. Further applications include brain disorders, cough treatment, analgesia, diarrhea treatment, and de-addiction. This breadth shows that opioid demand is not confined to a single therapeutic area.

Asia Pacific: The Fastest-Growing Region

North America held the largest revenue share in 2024, but Asia Pacific is expected to experience the highest CAGR during the forecast period, driven by high population density and growing healthcare demand. Aging societies, particularly Japan and China, are increasing the need for effective relief options. The report adds that mergers and acquisitions and strategic partnerships between global and local players are improving accessibility and fostering innovation. As an example, EVERSANA's partnership with Compai Pharma aims to expand commercialization services across Asia Pacific, leveraging local insights and distribution networks.

In India, substantial funding and foreign direct investment in the pharmaceutical sector are expected to support growth. According to Invest India, the country recorded USD 22.52 billion in foreign direct investment from 2000 to 2024, with the pharmaceutical industry accounting for about 3.32% of the total. The report says this inflow is facilitating advances in drug development, manufacturing, and distribution, and that government efforts to streamline regulation promote innovation.

Recent Regulatory Milestone

In June 2024, Trevena, Inc. announced that its partner in China, Jiangsu Nhwa Pharmaceutical Co., received approval from the National Medical Products Administration for OLINVYK. The opioid is authorized for adults with severe acute pain that requires intravenous opioid analgesics and is unresponsive to alternative treatments.

Competitive Dynamics and Outlook

The competitive landscape is evolving as established companies pursue innovation, partnerships, and acquisitions while emerging companies address specific market needs. Leading global players invest heavily in research and development, advanced manufacturing technologies, and substantial capital to maintain their advantage, while emerging companies introduce innovative devices and cater to specific market needs. Stringent government regulation is listed as a restraint. With the market moving from USD 24.14 billion in 2025 to USD 28.45 billion by 2034, differentiation through formulation innovation and regional partnerships will be central to competitive positioning.

More Trending Latest Reports By Polaris Market Research:

Gynecological Examination Chairs Market

Fluoropolymers Market

Safari Tourism Market

Enterprise Content Management Market

Automotive Ceramics Market

Mass Flow Controller Market

Hemophilia A Treatment Market

AI Trust, Risk and Security Management Market